Objective: Diabetes and peripheral arterial disease (PAD) are independently associated with increased risk of amputation. However, the effect of poor glycemic control on adverse limb events has not been studied. We examined the effects of poor glycemic control (high hemoglobin A 1c level) on the risk of amputation and modified major adverse limb events (mMALEs) after lower extremity revascularization.
Peripheral arterial disease (PAD) occurrence in patients with diabetes is three times greater than in those without diabetes, and its prevalence in diabetics older than 50 years is 29%. 1, 2 Diabetes causes endovascular dysfunction of microvascular and macrovascular circulation, leading to a state of inflammation and accelerated atherosclerosis. 3, 4 Patients with diabetes have more infrageniculate arterial involvement and frequently present with tissue loss and life-threatening lower extremity infections. 5, 6 Patients with diabetes and PAD have been shown to have a higher lifetime risk of amputation compared with those with either disease alone. 3, 7, 8 However, evidence regarding the mere presence of diabetes as a significant perioperative risk factor for amputation and mortality after peripheral revascularization has been conflicting. [9] [10] [11] [12] [13] The importance of glycemic control in the perioperative setting of lower extremity revascularization has not been well addressed. In randomized trials of diabetic patients, intensive glycemic control has had mixed results for major cardiovascular events. [14] [15] [16] Data are lacking in regard to the effect of glycemic control before surgery on amputation and limb-related outcomes, although glycemic control has been described as an important part of limb salvage in diabetics along with control of other risk factors. 4, 17 In a single-institution Japanese study, compared with nondiabetics, diabetic patients with hemoglobin A 1c (HbA 1c ) levels $6.8% had a significantly higher risk of major amputation than those with a lower HbA 1c level. 18 Another small study of infrapopliteal angioplasty in diabetic patients showed that high fasting blood glucose levels were associated with reduced primary patency and possibly amputations at 1 year. 19 The objective of our study was to determine the effect of poor glycemic control as defined by elevated perioperative HbA 1c on PAD outcomes of amputation and modified major adverse limb events (mMALEs) in patients undergoing vascular procedures in a large national cohort. Secondarily, we sought to determine the effect of elevated HbA 1c in patients without a preoperative diabetes mellitus (PreopDM) diagnosis but diagnosed after revascularization. We hypothesized that high HbA 1c levels would be associated with worse outcomes in those with or without PreopDM diagnosis and that there would be a dose-response effect of worse outcomes with higher HbA 1c levels.
METHODS
Sample and database. We reviewed national Veterans Health Administration data to identify 26,799 vascular patients with at least one PAD revascularization procedure (Supplementary Table I , online only) from 2003 to 2014 and HbA 1c measured within 6 months of the procedure. A comprehensive list of covariates including demographics (age at procedure, sex, race), body mass index, smoking (classified using a validated method 20 ), medications (antiplatelets, antihypertensives, statins, antiglycemics [insulin or oral antiglycemics], and cilostazol), PAD severity (claudication, rest pain, ulcer or gangrene, or unspecified), comorbidities (hypertension, coronary artery disease, chronic obstructive pulmonary disease, congestive heart failure, atrial fibrillation, carotid disease, depression, and chronic kidney disease or endstage renal disease), procedure location (infrainguinal vs suprainguinal reconstruction or combination), procedure type (open vs endovascular or hybrid), and laboratory values (total cholesterol, high-density lipoprotein, lowdensity lipoprotein, and creatinine) was abstracted from the Veterans Affairs (VA) Corporate Data Warehouse and VA Medical SAS administrative databases. All variables were measured closest to the vascular procedure date.
Study exposures and outcome. The exposure was defined as the closest HbA 1c measurement to the procedure date (within 6 months before or after). HbA 1c was dichotomized into normal (#7.0%) vs abnormal (>7.0%) readings. For our dose-response analysis, we further subdivided HbA 1c into four levels (#6.0%, 6.1%-7.0%, 7.1%-8.0%, and >8.0%). One inpatient or two outpatient visit International Classification of Diseases, Ninth Revision diagnosis codes for diabetes and a diabetes medication in the subject's record before the vascular procedure date were used to define PreopDM. Diabetes medications were classified into three categories (insulin, oral antiglycemics, or none).
The outcomes of interest were incident amputations (mid/hind-foot amputations, below-and above-knee amputations) and a composite incident amputation or repeated revascularization end point (mMALE) during follow-up including any endovascular or open revascularization for suprainguinal or infrainguinal disease Take Home Message: Of 26,799 patients who underwent revascularization for peripheral arterial disease, 60% had diabetes mellitus, many of whom were undiagnosed, and those who had diabetes with poor control had worse outcomes, including amputation and a major adverse limb event, when the hemoglobin A 1c level showed poor glycemic control (>7.0%). Recommendation: The authors recommend that all patients with peripheral arterial disease who require revascularization be screened for diabetes and that those with poor glycemic control be treated to achieve a hemoglobin A 1c level of <7.0%. Statistical analysis. Demographic and clinical variables were assessed for the entire cohort and stratified by HbA 1c (>7% vs #7%). Continuous variables were expressed as means (6 standard deviations) or as medians (6 interquartile ranges) if they were not normally distributed. Discrete variables were expressed as proportions. Proportions of missing data were also calculated and compared across subjects with any vs no missing data. Unadjusted associations for HbA 1c levels and risk of amputation and mMALE were obtained using Kaplan-Meier curves during the entire study period; subjects who did not experience an outcome were censored at death or December 31, 2015. HbA 1c was classified as a dichotomous exposure (>7% vs #7%) as well as a four-level exposure (#6.0%, 6.1%-7.0%, 7.1%-8.0%, and >8.0%).
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Cox proportional hazards regression models were then created to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for HbA 1c (four-level exposure) among all patients and by stratifying on PreopDM diagnosis. All Cox models adjusted for the covariates described before and procedure year. We excluded smoking because of >30% missing data. All variables were found to meet the proportional hazards assumption by log-log survival curves for amputation and mortality. Wald confidence limits were constructed for all HRs. In a sensitivity analysis, we added PreopDM medication use to the Cox models for those with a PreopDM diagnosis. The statistical analysis was done using SAS version 9.4 (SAS Institute, Cary, NC). Twosided P values < .05 were considered statistically significant. This study was approved by the Emory University Institutional Review Board and Atlanta VA Medical Center Research and Development Committee. Informed consent was waived for a retrospective cohort study design with no human patient contact and minimal privacy risks.
RESULTS
Our cohort consisted of 26,799 vascular patients with a median follow-up of 3.8 years for amputation and 3.5 years for the mMALE composite end point. The majority of the cohort was male (98.3%), with a mean age of 66.3 years (standard deviation, 8.9 years). There were 4369 (16.3%) patients with amputations and 10,580 (39.4%) patients with mMALE composite end point. The demographics and covariates of the cohort are listed in Table I . The mean HbA 1c level for the cohort was 6.4% (interquartile range, 5.80%-7.50%). High HbA 1c levels (>7%) were present in 33.2% of the cohort, whereas 59.9% had known diagnosis of PreopDM. A majority (91.6%) of patients with PreopDM had an abnormal perioperative HbA 1c level (Table I) . Patients with an abnormal HbA 1c level (>7%) were more likely to present with ulceration or gangrene (32%) and were more likely to be receiving insulin therapy for glycemic control (59.8%).
Unadjusted associations of HbA 1c , PreopDM, and mortality. The Kaplan-Meier curves in Fig 1 depict amputation-free survival and mMALE-free survival stratified by HbA 1c status as a dichotomous variable. Poor glycemic control as defined by a conventional HbA 1c level >7% shows a clear disadvantage with regard to amputation-free and mMALE-free survival over time. The amputation-free survival at 30 days, 1 year, 3 years, and 5 years was 96.1%, 90.7%, 87.9%, and 86% for the normal HbA 1c group, respectively; it was 94.1%, 84.7%, 79%, and Adjusted associations of HbA 1c with amputation and revascularization: all patients. In Cox proportional hazards regression, the effect of poor glycemic control persisted on increased risk of amputation and mMALE after adjusting for covariates described in the Methods section (Table II) . Given the strong dose-response association between HbA 1c level and amputation risk in the Kaplan-Meier analysis, the Cox regression models were run with a granular HbA 1c four-level classification. Among all patients, abnormal HbA 1c levels of 6.1% to 7.0%, 7.1% to 8.0%, and >8% were associated with 26% (HR, 1.26; 95% CI, 1.15-1.39), 53% (HR, 1.53; 95% CI, 1.37-1.7), and 105% (6.1%-7.0%) was not significant for risk of amputation or mMALE. Of note, these patients were not taking any diabetic medication preoperatively (Table III) 
DISCUSSION
Our study shows that elevated perioperative HbA 1c is associated with a higher incidence of long-term amputation and mMALE for PAD patients. The association is further strengthened on delineating HbA 1c levels (#6.0%, 6.1%-7.0%, 7.1%-8.0%, and >8.0%) to show a dose-response relationship between degree of glycemic control and adverse limb outcomes. Patients with the poorest glycemic control (HbA 1c >8.0%) are at twice the long-term risk of amputation and 33% higher risk for mMALE compared with those with a normal HbA 1c level. This association is attenuated but still significant in patients with PreopDM diagnosis and those receiving treatment for their diabetes, suggesting a possible role for better glycemic control perioperatively to improve long-term outcomes. Patients without recognized diabetes in the preoperative setting and elevated HbA 1c (>7.0%) are associated with the worst risk of amputation and mMALE in the cohort, suggesting the importance of preoperative recognition of diabetes before revascularization for PAD.
The impact of diabetes as a comorbid condition in patients with PAD is significant, both clinically and economically. 21 Most studies to date have explored only the presence of diabetes as a risk factor for lower extremity outcomes but not glycemic control. Malmstedt et al used a Swedish vascular registry to show that diabetes is associated with a lower amputation-free survival after leg bypass for CLI after adjusting for demographics, comorbidities, and other risk factors for amputation.
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In contrast, another European study showed no difference in limb salvage at 1 year for patients with and without diabetes undergoing femorodistal reconstruction for CLI. 13 18 In a separate single-center study, high fasting blood glucose concentration as a marker of glycemic control in patients undergoing infrapopliteal angioplasty was found to be associated with significantly decreased primary patency. 19 Because our main goal was to study the effect of glycemic control on lower extremity outcomes, we included all PAD revascularization procedures and not only endovascular procedures in our analysis. We adjusted for level of intervention (suprainguinal or infrainguinal), severity of PAD, and endovascular or open nature of intervention. Despite these adjustments, we found significant effect of glycemic control (in an incremental fashion) on long-term adverse limb events after revascularization in diabetic patients. Our study confirmed that presence of diabetes does have an impact on major amputation and adverse limb events, but the level of glycemic control had a stronger association with these outcomes. Among patients with a high HbA 1c level (>7%), 8.4% did not have known PreopDM diagnosis before surgery. Furthermore, we found a significantly higher risk of limb loss and need for revascularization in patients without PreopDM but who had evidence of poor glycemic control. This may suggest the need for screening for diabetes before a major revascularization procedure and perhaps using HbA 1c as a screening tool. HbA 1c concentration reflects mean blood glycemic levels during a 3-to 6-month period and has been used as a marker for glycemic control in a number of large clinical trials. [14] [15] [16] 23 Hyperglycemia augments the atherosclerotic process by several mechanisms, including by activating the protein kinase C pathway, increasing atherogenic lipid deposition and platelet activation, and inducing a hypercoagulable state. These pathways lead to a proinflammatory state that augments smooth muscle cell migration and proliferation and ultimately increases endothelial dysfunction and oxidative stress. 24 Higher concentrations of HbA 1c may promote arterial stiffness and accelerated atherosclerosis in proportion to the HbA 1c level, even at a level below the diagnostic threshold for diabetes. 25 According to a report from the Atherosclerosis Risk in Communities (ARIC) study, graded HbA 1c rise was associated with greater PAD incidence in diabetic adults, suggesting a role for advanced glycation end products and severity of hyperglycemia in accelerated atherosclerosis in the lower limbs. 26 The mechanism of association between poor glycemic control and adverse limb outcomes may also involve disparate pathways than atherosclerosis and inflammation. Poor glycemic control is associated with impaired wound healing, decreased immunity, and peripheral neuropathy through tissue accumulation and crosslinking in extracellular matrix, thus impairing healing of diabetic foot ulcers (DFUs) in patients with PAD. 27, 28 The role of intensive glucose control in the prevention of cardiovascular outcomes has been controversial. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial targeted treating patients aggressively to HbA 1c values below 6.0% vs using standard therapy to a value between 7.0% and 7.9% and found higher cardiovascular mortality in the intensively treated group at 3.5 years with no significant reduction in the number of cardiovascular events including nonfatal myocardial infarction and stroke. 14 31, 32 Compared with the lowest quartile of diabetic testing, diabetic patients in regions with the highest quartile of diabetic testing had significantly improved amputation-free survival (HR, 0.94) and MALE-free survival (HR, 0.92) persisting up to 2 years after lower extremity revascularization. Nondiabetic patients with CLI, in comparison, did not benefit to the same extent from undergoing revascularization in regions with high-quality outpatient diabetic care. 31 Another study in the VA system observed that patients with improved process measures like glucose control were less likely to undergo lower extremity bypass surgery or amputation. 33 The recent clinical practice guidelines from the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine recommend adequate glycemic control (HbA 1c < 7% with strategies to minimize hypoglycemia) to reduce the incidence of DFUs and infections, with subsequent risk of amputation (Grade 2B). 4 Our study findings support the role of glycemic control with a target of HbA 1c <7.0% to decrease amputation and adverse limb events in patients with PAD with PreopDM before revascularization. Our results also suggest possible usefulness of screening for diabetes using HbA 1c in PAD patients scheduled for revascularization. However, further prospective investigation will be required to verify whether glycemic interventions to target a modest HbA 1c goal of 7% offer risk reduction in PAD revascularization patients with known diabetes or those at risk for diabetes and whether surgery should be delayed in an elective setting to ensure a better perioperative glycemic control. Our study has several limitations. Data on laterality of vascular procedures and amputations were unavailable, possibly overestimating the number and timing of procedure-relevant outcomes. We only assessed the impact of perioperative HbA 1c level closest to the procedure. Patients could have had better glycemic control later on. Our study is observational, using administrative data, and the analysis may be susceptible to residual confounding. The nature of the database precludes access to technical details, such as runoff vessels or patency, and lacks ankle-brachial index data. The presence or absence of infection as well as extent of tissue loss is not well captured; therefore, we could not assign patients to some of the newer classifications being used for CLI, such as Wound, Ischemia, and foot Infection (WIfI). Only each subject's first vascular procedure during the study time frame (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) was included in the analysis. We adjusted for year of entry into the cohort, but our approach may have led to selection bias and has implications for the generalizability of the study. Our study is based on Veterans Health Administration data, and it is overwhelmingly composed of male patients. Results may differ in a non-VA population.
CONCLUSIONS
Poor glycemic control (high HbA 1c level) is incrementally associated with increased risk of amputation and mMALE in PAD patients undergoing revascularization. Presence of diabetes preoperatively is also an independent risk factor of adverse limb events. Patients with no known diabetes but impaired glycemic control are at worse risk of adverse limb-related outcomes with HbA 1c levels above 7.0% compared with those with PreopDM. Our results suggest a possible role of tighter glycemic control in reduction of amputation and need for further revascularization in diabetics as well as a possible utility of screening for diabetes using HbA 1c levels before revascularization for PAD rather than a pre-existing diagnosis of diabetes.
challenge would be to define the exposure period in such a cohort and how to make it comparable to those with HbA 1c levels. 4. That's a great question. I think for a start, we as vascular surgeons should routinely check HbA 1c and include that in our risk-benefit discussion with the patient on possible outcomes. We should screen for diabetes using HbA 1c based on our data. 
